Chemotherapy and dual immunotherapy combination nearly triples complete response rate in colorectal cancer
In patients with locally advanced colorectal cancer, combining intensified chemotherapy with the dual-antibody drug cadonilimab increased the pathologic complete response rate (pCR) to 26.8%, nearly three times higher than the 9.8% rate with standard therapy. This phase 2 trial,
2026-05-19


